• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    1/24/24 11:21:06 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    SC 13G/A 1 Intellia_Therap.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING INTELLIA THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45826J105 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO:45826J105 13G Page 2 of 5 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 4,485,854 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 4,735,861 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,735,861 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.29% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 45826J105 13G Page 3 of 5 Pages ITEM 1. (A) NAME OF ISSUER INTELLIA THERAPEUTICS INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 45826J105 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:45826J105 13G Page 4 of 5 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO:45826J105 13G Page 5 of 5 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.
    Get the next $NTLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    3/5/2025$30.00Buy
    H.C. Wainwright
    2/28/2025$45.00 → $13.00Overweight → Neutral
    Analyst
    2/28/2025$9.00Neutral → Sell
    Goldman
    1/27/2025$56.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    2/23/2024$136.00 → $32.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    4/13/2023$66.00Buy
    Canaccord Genuity
    More analyst ratings

    $NTLA
    Financials

    Live finance-specific insights

    See more
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug

      5/1/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

      Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En

      2/27/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bhanji Muna sold $2,252 worth of shares (265 units at $8.50), decreasing direct ownership by 1% to 19,203 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      5/1/25 4:24:22 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • EVP, Chief Technical Officer Clark Eliana was granted 32,000 shares and sold $6,104 worth of shares (679 units at $8.99), increasing direct ownership by 49% to 95,369 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      3/4/25 4:43:16 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Leonard John M was granted 136,000 shares, increasing direct ownership by 14% to 1,077,115 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      3/4/25 4:41:19 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Intellia Therapeutics Inc.

      10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)

      5/8/25 4:05:38 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      5/8/25 7:45:07 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFA14A filed by Intellia Therapeutics Inc.

      DEFA14A - Intellia Therapeutics, Inc. (0001652130) (Filer)

      4/30/25 4:12:04 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units ("RSUs") for 69,600 shares of Intellia's common stock, with one-third of such RSUs vesting on May 1, 2026, 2027 and 2028. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia through

      5/6/25 4:01:00 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug

      5/1/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

      Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

      11/16/24 10:16:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

      Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

      10/24/24 8:01:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

      - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

      10/10/24 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      2/13/24 5:07:59 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      1/29/24 4:00:59 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      1/24/24 11:21:06 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intellia Therapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00

      4/21/25 8:30:53 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • H.C. Wainwright initiated coverage on Intellia Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00

      3/5/25 7:39:47 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics downgraded by Analyst with a new price target

      Analyst downgraded Intellia Therapeutics from Overweight to Neutral and set a new price target of $13.00 from $45.00 previously

      2/28/25 7:27:33 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care